Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Much thanks for a very thoughtful post. Such posts are a rarity. Interestingly, last Spring when at least 10 countries reported that smokers were significantly underrepresented among those coming to the hospital with Covid, I panicked and ordered 3 bottles of Anatabloc from Pick (knowing I would get 6), because I feared they would discover anatabine could help and it would become unavailable.
No such luck. It was same old, same old! Nicotine was helping smokers, but nicotine was bad bad. Turns out a dozen years ago an intellectually disposed person, snake oil salesman, Jonnie Williams, figured out that nicotinic molecules could do amazing medical things. But the ignorant experts couldn't see it, and many millions of suffering humans have so far been deprived of the benefits of those molecules.
Smoking is a negative risk factor for Covid fatality. Smokers have better outcomes than non-smokers.
Anyone who followed the story of reduction of inflammation through use of Anatabloc (related to Akers (forthcoming after merger) MYMD-1 molecule) will find this fascinating. Remember the Johns Hopkins studies on thyroiditis (Hashimoto's).
Vitamin D and COVID 19: The Evidence for Prevention and Treatment of Coronavirus (SARS CoV 2) - the entire presentation is excellent!
MYMD-1, a Novel Immunometabolic Regulator, Ameliorates Autoimmune Thyroiditis via Suppression of Th1 Responses and TNF-a Release
January 2019, The Journal of Immunology 202(5):ji1801238
Abstract
Good info. Thanks!
A search of a number of financial websites shows that most are still showing AKERS outstanding shares as 8.9 million. However, TD Ameritrade shows 18.6 million, indicating recognition of the recent private placement of shares by AKERS.
On the recent "Akers Biosciences Business Update, Joshua Silverman, Lead Independent Director @ AKERS, said "I could say we feel very good about our current cash position with over $36 million and over $2 a share in cash".
This means that even with the very significant dilution of AKERS shares resulting from the more than doubling of shares outstanding, support for AKERS share price still remains at $2.00 a share.
Why wouldn't the FDA allow them to continue selling as a nutraceutical as long as the company made no claims about curing disease?
That always seemed to me to be an option.
Thanks for getting me to think about this again.
In most respects, leifsmith, I totally agree with you. But as to the FDA letter which removed anatabine from being available, they were correct that anatabine's professed ability to treat disease required that it achieve drug status as required by law. We were on our way with a phase 2 study to demonstrate that anatabine could impact Hashimoto's Thyroiditis when Rock Creek got itself into a funding disaster.
I think that's right.
The history of Star Scientific and its successor, Rock Creek Pharmaceuticals, tells the story of Jonnie Williams' product, Anatabloc. It had done a lot of good for a lot of people and was forced off the market by a threatening letter from the FDA. In my opinion that letter's only reason for existing was political, not medical.
Williams' current molecule MYMD-1 is a (some say improved) version of anatabine citrate (Anatabloc).
Akers might do well with this.
So what I’m hearing is MYMD is the catalyst to making our (AKERS) share value increase.
Agree - this story is now about MyMD.
Akers Biosciences In (AKER)
2.025 ? -0.015 (-0.74%)
Volume: 340,990 @12/07/20 2:56:40 PM EST
Bid Ask Day's Range
2.02 2.03 1.97 - 2.05
AKER Detailed Quote
The story here is no longer about Akers Biosystems, it's about MYMD Pharmaceuticals!
Well, We all know those goals will not be reached. Especially with the history of this company...
Interesting to note that while MYMD will remain a wholly owned subsidiary of Akers Bio until Spring, any significant news about MYMD will likely affect the price of AKER.
In that regard the merger agreement includes a provision for Milestone payments to MYMD stockholders if Akers Bio stock price reaches certain levels. The 1st Milestone payment of $20 million would be called for if "for at least 10 trading days during any 20 consecutive trading day period during the Milestone Period" the market capitalization of Akers "is equal to or greater than $500 million". With the current outstanding shares of AKER that would occur with AKER at $28 a share.
Another $10 million would need to be paid at $750 market capitalization, and $25 million at $1 billion, and $25 million for each additional $1 billion increase.
All of these payments can be made in Akers common stock!
Anyone ever interested in Anatabloc, anatabine-citrate, etc. might want to look at this:
https://finance.yahoo.com/news/akers-proposed-merger-partner-mymd-140000066.html
Today's BIG NEWS on MYMD
https://finance.yahoo.com/news/akers-proposed-merger-partner-mymd-140000066.html
penniespincher
MYMD Pharmaceuticals is currently a wholly owned subsidiary of Akers Biosciences, but when the reverse merger is completed around April 15 to May 15, AKER shares will be exchanged for MYMD shares in a ratio that leaves Akers shareholders owning 20% of MYMD.
Thanks - great research!
And, where's Jonnie?
I agree with your speculation however would that mean for AKERS shareholders be given the option to convert to MyMDPham?
Think I have finally got my head around this reverse merger. We start with 3 entities, Akers Biosciences = "AKERS", MYMD Pharmaceuticals = "MYMD", and XYZ Merger Sub Inc., a Florida corporation and a wholly-owned subsidiary of AKERS = "MERGER SUB". MERGER SUB, probably at the time of the merger agreement, will merge with and into MYMD, with MYMD being the surviving corporation, becoming a wholly-owned subsidiary of AKERS.
The final merger event will occur between April 15 and May 15, 2021 when AKERS will change its name from Akers Biosciences Inc. to MYMD Pharmaceuticals Inc., making MYMD the sole surviving corporate entity.
I read somewhere that the surviving company will be MyMD Pharmaceuticals. My undependable recollection is that the Akers stockholders are getting 20%, and that Akers is providing $3MM in funding. All would need verification. I've seen no trace of Jonnie in the deal, except to the usual Johns Hopkins researchers with whom he's worked for years.
Having much difficulty grasping what this merger is going to look like after it is completed. In usual Jonnie fashion it looks complicated. Is Akers going to come out of this as a private company as MYMD is merging with XYZ, a company created in Florida for the merger.
Informative article on the MyMD / Akers merger:
https://www.bioworld.com/articles/500127-mymd-heads-to-nasdaq-via-reverse-merger-with-akers-biosciences
Link provided by knuts4oe on the RCPI board - hoping to see him show up here soon.
Some stockholders of Akers, assisted by eager attorneys, seem to object to the relatively small part of the new company that will be assigned to Akers holders.
My belief is that when and if they understand the value MyMD is bringing into the new firm they will become happy with the part left for them.
MyMd is a venture of Jonnie Williams, who brought Anatabloc to the market.
There's a lot of interesting history there. William's company was once called Star Scientific, before becoming Rock Creek Pharmaceutical, now RCPI (in terminal bankruptcy) but still trading. I don't know if Williams has any relationship with RCPI.
The venture was ruined by a letter from the FDA suggesting that there would be trouble unless Anatabloc was removed from the market.
I've never understood how there could have been an honest and non-political basis for writing this letter. An attempt to discredit and replace the governor of Virginia, Bob McDonell, was somehow tangled up in this. He was friends with Williams and had hosted him at the Governor's Mansion.
The lives of many people were changed for the worse when Anatabloc was terminated. It had been doing a lot of good, without evidence of significant harm. The FDA letter did not allege harm. It said only, in effect, we think it would be good if you stopped.
It seems to me that MyMD has been carrying forward the work originally done as Star Scientific. I hope it succeeds. Anatabloc was a wonderful product.
Just In: $AKER SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Akers Biosciences, Inc. (NASDAQ:AKER)
BALA CYNWYD, PA / ACCESSWIRE / November 12, 2020 / Law Office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ:AKER) for possible breaches of fiduciary duty and other v...
Got this from AKER - SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Akers Biosciences, Inc. (NASDAQ:AKER)
* * $AKER Video Chart 11-12-2020 * *
Link to Video - click here to watch the technical chart video
JUST IN: $AKER ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc. PR Newswire NEW YORK, Nov. 12, 2020 NEW YORK , Nov. 12, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Akers Biosciences...
Read the whole news AKER - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc.
Breaking News: $AKER What Are Good Penny Stocks To Buy Right Now? 4 For Your Watch List?
Are These Good Penny Stocks To Buy Right Now? Looking for good penny stocks to buy right now? You and thousands of other traders are in the same position. Before you dive right into hitting the buy button, I think it’s important to understand what you’re buying, exactl...
Got this from AKER - What Are Good Penny Stocks To Buy Right Now? 4 For Your Watch List?
JUST IN: $AKER Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement
● Immunotherapies focused on age-related disorders and autoimmune diseases entering Phase 2 clinical trials ● Lead molecule MYMD-1 inhibits production of tumor necrosis factor alpha (TNF- α ), a cell signaling protein involved in systemic inf...
Find out more AKER - Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement
Akers Biosciences In (AKER)
2.25 ? 0.04 (1.81%)
Volume: 72,926 @10/23/20 7:57:53 PM EDT
Bid Ask Day's Range
2.15 2.5 2.19 - 2.25
AKER Detailed Quote
Akers Biosciences In (AKER)
2.22 ? -0.22 (-9.02%)
Volume: 462,076 @09/23/20 7:56:24 PM EDT
Bid Ask Day's Range
2.18 2.22 2.18 - 2.4493
AKER Detailed Quote
agree O/S 8.7mil
This gets any positive news and it will skyrocket in my opinion.
* * $AKER Video Chart 09-08-2020 * *
Link to Video - click here to watch the technical chart video
Akers Biosciences In (AKER)
2.2 ? -0.16 (-6.78%)
Volume: 944,414 @09/04/20 7:59:38 PM EDT
Bid Ask Day's Range
2.02 2.24 2.0 - 2.3162
AKER Detailed Quote
$AKER Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice. The test had two primary endpoints, safety and immune response, both of which were met. The candidate was well tolerated and safe in mice that received the intramuscular injection. A robust immune response was also observed.
The study consisted of 50 mice, divided into 10 cohorts dosed with 5, 10 and 20 micrograms of the PRAK-03202 vaccine candidate. The vaccine candidate was generally well tolerated and safe at all doses, with no adverse events reported. The vaccine candidate was safe even at higher doses and generated a robust immune response against the three SARS-Cov2 antigens, S, E, and M. PRAK3202 elicited neutralizing antibody titers levels in all the dose cohorts starting from 5 microgram to 20 microgram dose regimens. After three doses in mice, all the groups' cohorts showed binding antibody levels similar to convalescent patients’ levels.
Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented: “We are happy to report that the vaccine candidate study in mice has gone on well, and the results are positive and encouraging. We have engaged with the regulatory authorities in India and are working towards the next steps under their guidance.”
Premas will seek to further characterize the immune response in the near term, while pursuing additional safety studies and later stage animal testing with the goal of an investigational new drug (IND) submission to follow in the U.S. Premas continues to be engaged formally with authorities and the Drug Controller in India. Both Akers and Premas are also communicating with regulators in the United States.
Christopher Schreiber, Executive Chairman of Akers, stated, “We are very encouraged by the immune response and safety milestones met in this study organized with our partner, Premas. We are currently moving towards enhanced dialogue with regulatory bodies in both India and the United States and look forward to communicating updates with our investors in the near term.”
About Premas Biotech
Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation. Besides D-CryptTM the difficult to express proteins expression platform, Premas’ leading technologies include Axtex-4D™: an ex-vivo tissueoid generation platform and C-Qwence™: a fully human naive India based scFv antibody library. Further information is available on the Company’s website: www.premasbiotech.com
Contact email: contact@premasbiotech.com
About Akers Biosciences Inc.
Akers Biosciences is pursuing rapid development and manufacturing of a COVID-19 vaccine candidate in collaboration with Premas Biotech PVT Ltd. . In addition, the Company’s board of directors continues to evaluate strategic alternatives for the company to maximize shareholder value.
Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the company’s ability to achieve the expected benefits and costs of the transactions related to the acquisition of Cystron Biotech, LLC, including, the timing of, and the company’s ability to, obtain and maintain regulatory approvals for clinical trials of the company’s vaccine product candidate, the timing and results of the company’s planned clinical trials for its vaccine product candidate, the amount of funds the company requires for its vaccine product candidate, and the company’s ability to maintain its license with Premas Biotech PVT Ltd; challenges we may face in identifying, acquiring and operating new business opportunities; the outcome of litigation or other proceedings to which the company is subject or which it may become subject to in the future; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the company operates; the company’s ability to retain and attract senior management and other key employees; the company’s ability to quickly and effectively respond to new technological developments; the company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the company’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on the company’s results of operations, business plan and the global economy. A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the company’s filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission, as may be supplemented or amended by the company’s Quarterly Reports on Form 10-Q. The company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Additional information on the company and its products can be found at http://www.akersbio.com.
Contact:
Investor Relations: Hayden IR
Brett Mass, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
http://www.haydenir.com
$AKER Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/1/2020 4:35:18 PM
$AKER Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/31/2020 1:13:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/28/2020 5:04:52 PM
Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results GlobeNewswire Inc. - 8/27/2020 9:00:10 AM
N
$AKER Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/26/2020 7:04:26 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/18/2020 7:19:58 AM
$AKER Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/13/2020 8:41:22 AM
Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire Inc. - 8/11/2020 8:00:10 AM
Akers Biosciences In (AKER)
2.54 ? -0.08 (-3.05%)
Volume: 1,032,259 @09/02/20 4:13:56 PM EDT
Bid Ask Day's Range
2.53 2.54 2.41 - 2.62
AKER Detailed Quote
Watch for Big Grant Money from Indian Govt next few days
AKER bouncing after supposedly good scam results?
* * $AKER Video Chart 07-20-2020 * *
Link to Video - click here to watch the technical chart video
Aker having a nice move off bottom today
* * $AKER Video Chart 05-14-2020 * *
Link to Video - click here to watch the technical chart video
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2221
|
Created
|
01/15/15
|
Type
|
Free
|
Moderators |
Akers Biosciences mission is dedicated to solving global health challenges. Akers was founded in 1989 and has over
30 years of success in the health diagnostic industry having developed proprietary, in vitro diagnostic technologies.
In March of 2020, in an attempt to further their mission, Akers announced a strategic partnership with Premas Biotech.
The partnerships primary objective is to focus on novel vaccine candidates.
The emergence of this pandemic offers an opportunity for the company to be a solution in the healthcare space,
one that sets the stage for our next chapter of growth.
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.
The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.
Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.
We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
PIFA® technology is currently used in:
Licensing Availability
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.
Patent Information
Shs Outstand | 8.72M
|
Insider Trans | -0.83%
|
Book/sh | 2.96 |
Cash/sh | 2.00 |
Debt/Eq NO DEBT | 0.00 |
52W Range | 1.55 - 12.72 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |